$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000159075019000042 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$695.0K	$2.514M	$2.182M
YoY Change	-26.38%	15.22%	203.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.900M	$2.860M	$2.670M
YoY Change	7.41%	7.12%	3.49%
% of Gross Profit
Research & Development	$9.027M	$8.599M	$8.375M
YoY Change	22.0%	2.67%	52.63%
% of Gross Profit
Depreciation & Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$11.93M	$11.46M	$11.04M
YoY Change	18.13%	3.74%	36.87%
Operating Profit	-$11.23M	-$8.942M	-$8.861M
YoY Change	22.72%	0.91%	20.56%
Interest Expense	$0.00	$50.00K	$150.0K
YoY Change	-100.0%	-66.67%	275.0%
% of Operating Profit
Other Income/Expense, Net	$204.0K	$275.0K	$361.0K
YoY Change	-43.65%	-23.82%	253.92%
Pretax Income	-$11.23M	-$8.900M	-$8.710M
YoY Change	24.64%	2.18%	19.15%
Income Tax
% Of Pretax Income
Net Earnings	-$11.23M	-$8.896M	-$8.714M
YoY Change	24.63%	2.09%	19.17%
Net Earnings / Revenue	-1615.83%	-353.86%	-399.36%
Basic Earnings Per Share
Diluted Earnings Per Share	-$5.425M	-$4.300M	-$4.312M
COMMON SHARES
Basic Shares Outstanding	31.05M shares	30.93M shares	30.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$33.80M	$43.90M	$76.30M
YoY Change	-52.06%	-42.46%	64.79%
Cash & Equivalents	$24.86M	$24.01M	$43.40M
Short-Term Investments	$9.000M	$19.90M	$32.90M
Other Short-Term Assets	$3.400M	$3.800M	$3.800M
YoY Change	-10.53%	0.0%	52.0%
Inventory
Prepaid Expenses
Receivables	$979.0K	$325.0K	$1.198M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$38.22M	$48.08M	$81.22M
YoY Change	-49.55%	-40.8%	64.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$596.0K	$652.0K	$614.0K
YoY Change	-20.64%	6.19%	-1.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$50.00K	$50.00K
YoY Change	-100.0%	0.0%	0.0%
Total Long-Term Assets	$596.0K	$702.0K	$664.0K
YoY Change	-25.59%	5.72%	-1.78%
TOTAL ASSETS
Total Short-Term Assets	$38.22M	$48.08M	$81.22M
Total Long-Term Assets	$596.0K	$702.0K	$664.0K
Total Assets	$38.81M	$48.78M	$81.89M
YoY Change	-49.3%	-40.43%	63.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.556M	$1.232M	$461.0K
YoY Change	29.02%	167.25%	-27.06%
Accrued Expenses	$4.857M	$3.946M	$3.534M
YoY Change	12.02%	11.66%	-12.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.000M	$4.000M	$300.0K
YoY Change	207.69%	1233.33%	-85.0%
Total Short-Term Liabilities	$10.39M	$9.148M	$4.284M
YoY Change	51.98%	113.54%	-35.38%
LONG-TERM LIABILITIES
Long-Term Debt	$5.300M	$6.200M	$9.800M
YoY Change	-40.45%	-36.73%	415.79%
Other Long-Term Liabilities	$0.00	$0.00	$110.0K
YoY Change	-100.0%	-100.0%	-41.8%
Total Long-Term Liabilities	$0.00	$0.00	$110.0K
YoY Change	-100.0%	-100.0%	-41.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.39M	$9.148M	$4.284M
Total Long-Term Liabilities	$0.00	$0.00	$110.0K
Total Liabilities	$15.64M	$15.35M	$14.22M
YoY Change	-1.21%	7.94%	63.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$158.1M	-$146.8M	-$107.0M
YoY Change	36.32%	37.26%	31.45%
Common Stock	$312.0K	$310.0K	$306.0K
YoY Change	1.3%	1.31%	42.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$23.17M	$33.44M	$67.67M
YoY Change
Total Liabilities & Shareholders Equity	$38.81M	$48.78M	$81.89M
YoY Change	-49.3%	-40.43%	63.69%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$11.23M	-$8.896M	-$8.714M
YoY Change	24.63%	2.09%	19.17%
Depreciation, Depletion And Amortization	$100.0K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	0.0%
Cash From Operating Activities	-$9.270M	-$7.170M	-$4.510M
YoY Change	36.32%	58.98%	-36.3%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$30.00K	-$90.00K
YoY Change	-95.0%	-66.67%	-18.18%
Acquisitions
YoY Change
Other Investing Activities	$11.04M	$13.05M	-$32.80M
YoY Change	-290.34%	-139.79%
Cash From Investing Activities	$11.02M	$13.03M	-$32.88M
YoY Change	-283.06%	-139.63%	29790.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-910.0K	-40.00K	2.700M
YoY Change	-181.25%	-101.48%	-455.26%
NET CHANGE
Cash From Operating Activities	-9.270M	-7.170M	-4.510M
Cash From Investing Activities	11.02M	13.03M	-32.88M
Cash From Financing Activities	-910.0K	-40.00K	2.700M
Net Change In Cash	840.0K	5.820M	-34.69M
YoY Change	-107.18%	-116.78%	336.35%
FREE CASH FLOW
Cash From Operating Activities	-$9.270M	-$7.170M	-$4.510M
Capital Expenditures	-$10.00K	-$30.00K	-$90.00K
Free Cash Flow	-$9.260M	-$7.140M	-$4.420M
YoY Change	40.3%	61.54%	-36.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	614000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24000	USD
	dei	Document Type DocumentType	10-Q
CY2019Q2	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1798000	USD
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	54000	USD
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31045173	shares
	mgen	Amortization Of Stock Issuance Costs AmortizationOfStockIssuanceCosts	1000	USD
CY2019Q2	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	105000000	shares
CY2019Q2	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	1000000	USD
	mgen	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	2	renewal_term
CY2018Q4	mgen	Contract With Customer Asset Incurred But Not Yet Billed ContractWithCustomerAssetIncurredButNotYetBilled	500000	USD
	mgen	License Fee Expense Milestone Reached LicenseFeeExpenseMilestoneReached	700000	USD
	mgen	License Fee Expense Milestone Reached LicenseFeeExpenseMilestoneReached	100000	USD
CY2018Q4	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	367000	USD
CY2019Q2	mgen	Long Term Debt Accumulated Accretion Of Final Payment Fee LongTermDebtAccumulatedAccretionOfFinalPaymentFee	530000	USD
CY2019Q2	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	343000	USD
CY2018Q4	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	33000	USD
CY2019Q2	mgen	Accrued Liabilities Equipmentand Lab Materials AccruedLiabilitiesEquipmentandLabMaterials	67000	USD
CY2018Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2019Q2	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	82000	USD
CY2018Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	1129000	USD
CY2018Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
CY2019Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	USD
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	USD
	mgen	Sharebased Compensation Arrangement By Sharebased Payment Award Number Of Shares Authorized Percent Of Common Stock Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAuthorizedPercentOfCommonStockOutstanding	0.04
CY2019Q2	mgen	Sharebased Compensation Arrangementby Sharebased Payment Award Equity Awards Outstanding SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding	2873469	shares
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	571000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1232000	USD
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	MIRAGEN THERAPEUTICS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	376000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	325000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	61000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	325000	USD
	us-gaap	Accretion Expense AccretionExpense	189000	USD
	us-gaap	Accretion Expense AccretionExpense	186000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3868000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3946000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	246000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	218000	USD
CY2018Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	124000	USD
CY2019Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	93000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3090000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3220000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177335000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179937000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	790000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	984000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1018000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1075000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1774000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2093000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3587000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4541000	shares
CY2018Q4	us-gaap	Assets Assets	66147000	USD
CY2019Q2	us-gaap	Assets Assets	48782000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	65370000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	48080000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	29900000	USD
CY2019Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	19900000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	29900000	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	19900000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47441000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43402000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32606000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24007000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4039000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8599000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	43900000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	953216	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30839463	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31037363	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30839463	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31037363	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	308000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	310000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8710000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2018Q4	us-gaap	Liabilities Liabilities	14803000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	15345000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8887000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20511000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13371000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1206000	USD
CY2019Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2018Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1704000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66147000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48782000	USD
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2019Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9667000	USD
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	69000	USD
CY2019Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	46000	USD
CY2018Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138000	USD
CY2019Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	144000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M20D
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2668000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5658000	USD
CY2019Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2857000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6214000	USD
CY2018Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-445000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	661000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-258000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	301000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	501000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	28000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	846000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	944000	USD
CY2018Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	214000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	423000	USD
CY2019Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	229000	USD
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	461000	USD
	us-gaap	Interest Paid Net InterestPaidNet	232000	USD
	us-gaap	Interest Paid Net InterestPaidNet	277000	USD
CY2018Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2019Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6733000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9148000	USD
CY2019Q2	us-gaap	Long Term Debt LongTermDebt	9667000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13375000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-11629000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-8896000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-20525000	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8714000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8896000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20525000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	361000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	528000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	275000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3667000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	4000000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2000000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	8004000	USD
CY2019Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	6181000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40812000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	179000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32984000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10205000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11867000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18983000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-4661000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-8714000	USD
CY2018Q4	us-gaap	Notes Payable NotesPayable	10298000	USD
CY2019Q2	us-gaap	Notes Payable NotesPayable	10151000	USD
CY2018Q4	us-gaap	Notes Payable Current NotesPayableCurrent	2294000	USD
CY2019Q2	us-gaap	Notes Payable Current NotesPayableCurrent	3970000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	11043000	USD
	us-gaap	Operating Expenses OperatingExpenses	20446000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	11456000	USD
	us-gaap	Operating Expenses OperatingExpenses	23564000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8861000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13480000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8942000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-20678000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	479000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	202000	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	277000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	174000	USD
CY2019Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	139000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	50000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	4000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	4000	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	84000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2018Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2019Q2	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	5000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	9000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	14000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	66000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	32795000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28726000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	189000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	USD
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2865000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3808000	USD
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	110000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	39000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	146000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	15000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3817000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3872000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	727000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	652000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	333000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8375000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14788000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8599000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17350000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-126296000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146821000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2182000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6966000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2514000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2886000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1774000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2093000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	902720	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1233578	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4182404	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	29875000	USD
CY2019Q2	us-gaap	Short Term Investments ShortTermInvestments	19940000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	110000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	84000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	112000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	34000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	38510000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	72706000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	67671000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	51344000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	40956000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	33437000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30295200	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28399687	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30983918	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30935272	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001590750-19-000042-index-headers.html	Edgar Link	pending
0001590750-19-000042-index.html	Edgar Link	pending
0001590750-19-000042.txt	Edgar Link	pending
0001590750-19-000042-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
mgen-20190630.xml	Edgar Link	completed
mgen-20190630.xsd	Edgar Link	pending
mgen-20190630_cal.xml	Edgar Link	unprocessable
mgen-20190630_def.xml	Edgar Link	unprocessable
mgen-20190630_lab.xml	Edgar Link	unprocessable
mgen-20190630_pre.xml	Edgar Link	unprocessable
mgen-q22019x10q.htm	Edgar Link	pending
mgen-q22019xex311.htm	Edgar Link	pending
mgen-q22019xex312.htm	Edgar Link	pending
mgen-q22019xex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2019 Q3 Form 10-Q Financial Statement

#000159075019000042 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2019 Q3 Form 10-Q Financial Statement

#000159075019000042 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn